Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome)

[1]  D. Chu,et al.  Dromedary Camels and the Transmission of Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) , 2015, Transboundary and emerging diseases.

[2]  A. Tamin,et al.  Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.

[3]  D. Feikin,et al.  Middle East Respiratory Syndrome Coronavirus Transmission in Extended Family, Saudi Arabia, 2014 , 2016, Emerging infectious diseases.

[4]  A. Assiri,et al.  Middle East Respiratory Syndrome Coronavirus Infection During Pregnancy: A Report of 5 Cases From Saudi Arabia , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Algahtani,et al.  Neurological Complications of Middle East Respiratory Syndrome Coronavirus: A Report of Two Cases and Review of the Literature , 2016, Case reports in neurological medicine.

[6]  A. Kallen,et al.  Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi , 2016, Emerging infectious diseases.

[7]  Lisa E. Gralinski,et al.  SARS-like WIV1-CoV poised for human emergence , 2016, Proceedings of the National Academy of Sciences.

[8]  K. Moon,et al.  A Case Report of a Middle East Respiratory Syndrome Survivor with Kidney Biopsy Results , 2016, Journal of Korean medical science.

[9]  G. Wali,et al.  Impact of Middle East Respiratory Syndrome coronavirus (MERS‐CoV) on pregnancy and perinatal outcome , 2016, BMC Infectious Diseases.

[10]  Faeka El Sayed,et al.  Middle East Respiratory Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates, 2013 , 2016, Emerging infectious diseases.

[11]  M. Peiris,et al.  Absence of Middle East Respiratory Syndrome Coronavirus in Camelids, Kazakhstan, 2015 , 2016, Emerging infectious diseases.

[12]  G. Olinger,et al.  Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo , 2016, Science Translational Medicine.

[13]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[14]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[15]  D. Swerdlow,et al.  Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 , 2016, The American Journal of Pathology.

[16]  Ulas Bagci,et al.  3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 , 2016, Virology.

[17]  Mohammad A. Almazroa,et al.  Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014 , 2016, Emerging infectious diseases.

[18]  C. Ki,et al.  Survey of Clinical Laboratory Practices for 2015 Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea , 2015, Annals of laboratory medicine.

[19]  Z. Memish,et al.  Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Y. Arabi,et al.  Critically ill patients with Middle East respiratory syndrome coronavirus infection , 2014, Critical care.

[21]  E. Lau,et al.  Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea , 2015, Emerging infectious diseases.

[22]  P. G. Choe,et al.  Middle East Respiratory Syndrome Coronavirus Superspreading Event Involving 81 Persons, Korea 2015 , 2015, Journal of Korean medical science.

[23]  Joshua C. Johnson,et al.  Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease , 2015, Virology.

[24]  Dae-Won Kim,et al.  Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015 , 2015, Osong Public Health and Research Perspectives.

[25]  R. Baric,et al.  Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.

[26]  Jian-Piao Cai,et al.  Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.

[27]  L. Poon,et al.  Absence of MERS-Coronavirus in Bactrian Camels, Southern Mongolia, November 2014 , 2015, Emerging infectious diseases.

[28]  F. Farahat,et al.  IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study , 2015, The Journal of antimicrobial chemotherapy.

[29]  Victor M Corman,et al.  Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study , 2015, The Lancet Infectious Diseases.

[30]  L. Poon,et al.  Lack of Middle East Respiratory Syndrome Coronavirus Transmission from Infected Camels , 2015, Emerging infectious diseases.

[31]  M. Alghamdi,et al.  MERS CoV Infection in Two Renal Transplant Recipients: Case Report , 2015, American Journal of Transplantation.

[32]  Susan I Gerber,et al.  2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. , 2015, The New England journal of medicine.

[33]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[34]  Z. Memish,et al.  Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia , 2014, International Journal of Infectious Diseases.

[35]  Z. Memish,et al.  Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study , 2014, The Lancet Infectious Diseases.

[36]  A. Ajlan,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. , 2014, AJR. American journal of roentgenology.

[37]  M. Koopmans,et al.  Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen , 2014, International Journal of Antimicrobial Agents.

[38]  Z. Memish,et al.  Transmission of MERS-coronavirus in household contacts. , 2014, The New England journal of medicine.

[39]  J. Rossignol.  Nitazoxanide: A first-in-class broad-spectrum antiviral agent , 2014, Antiviral Research.

[40]  R. Favory,et al.  Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases , 2014, Journal of Clinical Virology.

[41]  Y. Guan,et al.  Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[42]  D. Hui,et al.  Infection control and MERS-CoV in health-care workers , 2014, The Lancet.

[43]  T. Bestebroer,et al.  Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.

[44]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[45]  K. Yuen,et al.  Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.

[46]  R. Baric,et al.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.

[47]  M. Titécat,et al.  Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside? , 2014, PloS one.

[48]  Noha H Farag,et al.  Stillbirth During Infection With Middle East Respiratory Syndrome Coronavirus , 2014, The Journal of infectious diseases.

[49]  Z. Memish,et al.  Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study , 2014, International Journal of Infectious Diseases.

[50]  I. Yu,et al.  Severe Acute Respiratory Syndrome Beyond Amoy Gardens: Completing the Incomplete Legacy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  D. Hui,et al.  Advancing Priority Research on the Middle East Respiratory Syndrome Coronavirus , 2013, The Journal of infectious diseases.

[52]  K. To,et al.  Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis , 2013, The Journal of infectious diseases.

[53]  P. Formenty,et al.  State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans , 2013, PLoS currents.

[54]  Amit Kapoor,et al.  Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia , 2013, Emerging infectious diseases.

[55]  K. To,et al.  Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.

[56]  Christian Drosten,et al.  Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. , 2013, American journal of respiratory and critical care medicine.

[57]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[58]  T. Bestebroer,et al.  MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment , 2013, The Journal of general virology.

[59]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[60]  Z. Memish,et al.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.

[61]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[62]  Julien Riou,et al.  Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk , 2013, The Lancet.

[63]  Ziad A Memish,et al.  Family cluster of Middle East respiratory syndrome coronavirus infections. , 2013, The New England journal of medicine.

[64]  Victor M Corman,et al.  Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection , 2013, The Lancet Infectious Diseases.

[65]  A. Fontanet,et al.  Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission , 2013, The Lancet.

[66]  H. Feldmann,et al.  Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin , 2013, Scientific Reports.

[67]  D. Hui,et al.  Adjunctive therapies and immunomodulatory agents in the management of severe influenza , 2013, Antiviral Research.

[68]  Y. Guan,et al.  Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures , 2013, Journal of Virology.

[69]  K. To,et al.  Differential Cell Line Susceptibility to the Emerging Novel Human Betacoronavirus 2c EMC/2012: Implications for Disease Pathogenesis and Clinical Manifestation , 2013, The Journal of infectious diseases.

[70]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[71]  Chantal Reusken,et al.  Human Betacoronavirus 2c EMC/2012–related Viruses in Bats, Ghana and Europe , 2013, Emerging infectious diseases.

[72]  S. Alqasrawi,et al.  Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. , 2013, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[73]  M. Buchmeier,et al.  Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines , 2012, mBio.

[74]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[75]  Khai Tran,et al.  Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review , 2012, PloS one.

[76]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[77]  W. Liu,et al.  IL-12 RB1 Genetic Variants Contribute to Human Susceptibility to Severe Acute Respiratory Syndrome Infection among Chinese , 2008, PloS one.

[78]  Zhìhóng Hú,et al.  A review of studies on animal reservoirs of the SARS coronavirus , 2007, Virus Research.

[79]  I. Yu,et al.  Why Did Outbreaks of Severe Acute Respiratory Syndrome Occur in Some Hospital Wards but Not in Others? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  Kwok-Hung Chan,et al.  Viral Load Distribution in SARS Outbreak , 2005, Emerging infectious diseases.

[81]  Y. Guan,et al.  SARS-CoV Infection in a Restaurant from Palm Civet , 2005, Emerging infectious diseases.

[82]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[83]  Kwok-Hung Chan,et al.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S. Diamond,et al.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Fraser,et al.  Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups , 2005, Epidemiology and Infection.

[86]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[87]  J. Sung,et al.  The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. , 2005, The Journal of general virology.

[88]  J. Peiris,et al.  Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.

[89]  S. Paton,et al.  Detection of Airborne Severe Acute Respiratory Syndrome (SARS) Coronavirus and Environmental Contamination in SARS Outbreak Units , 2005, The Journal of infectious diseases.

[90]  Tze Wai Wong,et al.  Temporal-Spatial Analysis of Severe Acute Respiratory Syndrome among Hospital Inpatients , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  Jun Xu,et al.  Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. , 2005, American journal of respiratory and critical care medicine.

[92]  A. Ahuja,et al.  Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. , 2005, Radiology.

[93]  Guo-Ping Zhao,et al.  Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[94]  S. Lai,et al.  Severe acute respiratory syndrome: clinical features , 2005, Coronaviruses with Special Emphasis on First Insights Concerning SARS.

[95]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[96]  W. Hong,et al.  Overexpression of 7a, a Protein Specifically Encoded by the Severe Acute Respiratory Syndrome Coronavirus, Induces Apoptosis via a Caspase-Dependent Pathway , 2004, Journal of Virology.

[97]  Christophe Fraser,et al.  The Epidemiology of Severe Acute Respiratory Syndrome in the 2003 Hong Kong Epidemic: An Analysis of All 1755 Patients , 2004, Annals of Internal Medicine.

[98]  V. Wong,et al.  Severe acute respiratory syndrome: correlation between clinical outcome and radiologic features. , 2004, Radiology.

[99]  V. Wong,et al.  Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.

[100]  J. Sung,et al.  Persistent infection of SARS coronavirus in colonic cells in vitro , 2004, Journal of medical virology.

[101]  T. Ng,et al.  Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome , 2004, American Journal of Obstetrics and Gynecology.

[102]  S. Teoh,et al.  The severe acute respiratory syndrome coronavirus in tears , 2004, British Journal of Ophthalmology.

[103]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.

[104]  H. Field,et al.  Epidemiologic Clues to SARS Origin in China , 2004, Emerging infectious diseases.

[105]  V. Wong,et al.  Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.

[106]  Tze Wai Wong,et al.  Evidence of airborne transmission of the severe acute respiratory syndrome virus. , 2004, The New England journal of medicine.

[107]  F. Aoki,et al.  Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.

[108]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[109]  J. Sung,et al.  Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS) , 2004, Journal of Clinical Pathology.

[110]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[111]  Ton de Jong,et al.  Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.

[112]  D. Hui,et al.  Index Patient and SARS Outbreak in Hong Kong , 2004, Emerging infectious diseases.

[113]  Peter B. Jahrling,et al.  Interferon-β 1a and SARS Coronavirus Replication , 2004, Emerging infectious diseases.

[114]  K. Yuen,et al.  Possible Central Nervous System Infection by SARS Coronavirus , 2004, Emerging infectious diseases.

[115]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[116]  Ming Wang,et al.  [Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China]. , 2004, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[117]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[118]  V. Wong,et al.  Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.

[119]  J. Sung,et al.  Detection of SARS Coronavirus RNA in the Cerebrospinal Fluid of a Patient with Severe Acute Respiratory Syndrome , 2003, Clinical chemistry.

[120]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[121]  D. Hui,et al.  SARS: clinical features and diagnosis , 2003, Respirology.

[122]  O. Tsang,et al.  Coronavirus-positive Nasopharyngeal Aspirate as Predictor for Severe Acute Respiratory Syndrome Mortality , 2003, Emerging infectious diseases.

[123]  J. Peiris,et al.  Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 , 2003, The Lancet.

[124]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[125]  Hisashi Moriguchi,et al.  Treatment of SARS with human interferons , 2003, The Lancet.

[126]  J. Sung,et al.  Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection , 2003 .

[127]  J. Sung,et al.  Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection , 2003, Gastroenterology.

[128]  P. Hawkey,et al.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.

[129]  Junya Fukuoka,et al.  Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore , 2003, Human Pathology.

[130]  Anil T Ahuja,et al.  Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. , 2003, Radiology.

[131]  Xin Li,et al.  Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. , 2003, The New England journal of medicine.

[132]  J. Peiris,et al.  Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.

[133]  K. Wong,et al.  Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. , 2003, The Journal of bone and joint surgery. American volume.

[134]  J. Sung,et al.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.

[135]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[136]  Y. Leo,et al.  Severe Acute Respiratory Syndrome (SARS) in Singapore: Clinical Features of Index Patient and Initial Contacts , 2003, Emerging infectious diseases.

[137]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[138]  Yi Guan,et al.  Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.

[139]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[140]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[141]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[142]  P. Chan,et al.  Clinical presentations and outcome of severe acute respiratory syndrome in children , 2003, The Lancet.

[143]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[144]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.